Bentley Pharmaceuticals Reports Positive Results with Nasulin(TM) Intranasal Insulin Spray at the American Diabetes Association Meeting
EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced positive clinical results in three Company-sponsored studies of its investigational drug, Nasulin™, an intranasal insulin spray. The data were presented this past weekend at the American Diabetes Association 67th Scientific Sessions in Chicago.